Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Harvard Business School
McKinsey
McKesson
Boehringer Ingelheim

Last Updated: January 18, 2020

DrugPatentWatch Database Preview

Mylan Pharms Inc Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the competitive landscape for MYLAN PHARMS INC, and what generic and branded alternatives to MYLAN PHARMS INC drugs are available?

MYLAN PHARMS INC has one hundred and sixteen approved drugs.

There are twenty-one tentative approvals on MYLAN PHARMS INC drugs.

Summary for Mylan Pharms Inc
US Patents:0
Tradenames:103
Ingredients:101
NDAs:116

Drugs and US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Pharms Inc ARMODAFINIL armodafinil TABLET;ORAL 200043-002 Jun 1, 2012 AB RX No No   Start Trial   Start Trial
Mylan Pharms Inc CIPROFLOXACIN EXTENDED RELEASE ciprofloxacin; ciprofloxacin hydrochloride TABLET, EXTENDED RELEASE;ORAL 078183-001 Mar 22, 2007 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc PREDNISOLONE SODIUM PHOSPHATE prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 202179-001 Apr 10, 2013 AB RX No No   Start Trial   Start Trial
Mylan Pharms Inc SIMVASTATIN simvastatin TABLET;ORAL 090868-005 Jun 8, 2010 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc CLOPIDOGREL BISULFATE clopidogrel bisulfate TABLET;ORAL 077665-002 May 17, 2012 DISCN No No   Start Trial   Start Trial
Mylan Pharms Inc VALACYCLOVIR HYDROCHLORIDE valacyclovir hydrochloride TABLET;ORAL 078518-001 May 24, 2010 AB RX No No   Start Trial   Start Trial
Mylan Pharms Inc IRBESARTAN irbesartan TABLET;ORAL 200461-002 Sep 27, 2012 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Mylan Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Pharms Inc MAXZIDE-25 hydrochlorothiazide; triamterene TABLET;ORAL 019129-003 May 13, 1988 4,444,769   Start Trial
Mylan Pharms Inc AVITA tretinoin CREAM;TOPICAL 020404-003 Jan 14, 1997 4,971,800   Start Trial
Mylan Pharms Inc AVITA tretinoin CREAM;TOPICAL 020404-003 Jan 14, 1997 5,045,317   Start Trial
Mylan Pharms Inc MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,444,769   Start Trial
Mylan Pharms Inc MAXZIDE hydrochlorothiazide; triamterene TABLET;ORAL 019129-001 Oct 22, 1984 4,105,783   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Express Scripts
McKesson
Baxter
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.